SERIOUS INFUSION REACTIONS AND NEUROTOXICITY
See full prescribing information for complete boxed warning.
- TRADE NAME: Unituxin (United Therapeutics)
- INDICATIONS: High-risk neuroblastoma in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and isotretinoin (13-cis-retinoic acid), in pediatric patients who achieve at least a partial response to prior first-line multiagent, multimodality therapy
- CLASS: GD2-binding monoclonal antibody, Monoclonal antibody
- HALF-LIFE: 10 days
- FDA APPROVAL DATE: 03/10/2015
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
None known - PREGNANCY: May cause fetal harm
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of dinutuximab in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 07/31/2023
